A citation-based method for searching scientific literature

Jean Charles Nault, Maxime Mallet, Camilla Pilati, Julien Calderaro, Paulette Bioulac-Sage, Christophe Laurent, Alexis Laurent, Daniel Cherqui, Charles Balabaud, Jessica Zucman-Rossi. Nat Commun 2013
Times Cited: 354







List of co-cited articles
920 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets.
Kornelius Schulze, Sandrine Imbeaud, Eric Letouzé, Ludmil B Alexandrov, Julien Calderaro, Sandra Rebouissou, Gabrielle Couchy, Clément Meiller, Jayendra Shinde, Frederic Soysouvanh,[...]. Nat Genet 2015
733
38

Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis.
Jean Charles Nault, Julien Calderaro, Luca Di Tommaso, Charles Balabaud, Elie Serge Zafrani, Paulette Bioulac-Sage, Massimo Roncalli, Jessica Zucman-Rossi. Hepatology 2014
166
37

Trans-ancestry mutational landscape of hepatocellular carcinoma genomes.
Yasushi Totoki, Kenji Tatsuno, Kyle R Covington, Hiroki Ueda, Chad J Creighton, Mamoru Kato, Shingo Tsuji, Lawrence A Donehower, Betty L Slagle, Hiromi Nakamura,[...]. Nat Genet 2014
396
36


Genetic Landscape and Biomarkers of Hepatocellular Carcinoma.
Jessica Zucman-Rossi, Augusto Villanueva, Jean-Charles Nault, Josep M Llovet. Gastroenterology 2015
517
27

Highly recurrent TERT promoter mutations in human melanoma.
Franklin W Huang, Eran Hodis, Mary Jue Xu, Gregory V Kryukov, Lynda Chin, Levi A Garraway. Science 2013
22

Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma.
Wing-Kin Sung, Hancheng Zheng, Shuyu Li, Ronghua Chen, Xiao Liu, Yingrui Li, Nikki P Lee, Wah H Lee, Pramila N Ariyaratne, Chandana Tennakoon,[...]. Nat Genet 2012
518
21

Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma.
Cécile Guichard, Giuliana Amaddeo, Sandrine Imbeaud, Yannick Ladeiro, Laura Pelletier, Ichrafe Ben Maad, Julien Calderaro, Paulette Bioulac-Sage, Mélanie Letexier, Françoise Degos,[...]. Nat Genet 2012
849
21

Sorafenib in advanced hepatocellular carcinoma.
Josep M Llovet, Sergio Ricci, Vincenzo Mazzaferro, Philip Hilgard, Edward Gane, Jean-Frédéric Blanc, Andre Cosme de Oliveira, Armando Santoro, Jean-Luc Raoul, Alejandro Forner,[...]. N Engl J Med 2008
20

Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets.
Sandrine Boyault, David S Rickman, Aurélien de Reyniès, Charles Balabaud, Sandra Rebouissou, Emmanuelle Jeannot, Aurélie Hérault, Jean Saric, Jacques Belghiti, Dominique Franco,[...]. Hepatology 2007
677
18

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Jordi Bruix, Shukui Qin, Philippe Merle, Alessandro Granito, Yi-Hsiang Huang, György Bodoky, Marc Pracht, Osamu Yokosuka, Olivier Rosmorduc, Valeriy Breder,[...]. Lancet 2017
18

TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal.
Patrick J Killela, Zachary J Reitman, Yuchen Jiao, Chetan Bettegowda, Nishant Agrawal, Luis A Diaz, Allan H Friedman, Henry Friedman, Gary L Gallia, Beppino C Giovanella,[...]. Proc Natl Acad Sci U S A 2013
829
18

TERT promoter mutations in familial and sporadic melanoma.
Susanne Horn, Adina Figl, P Sivaramakrishna Rachakonda, Christine Fischer, Antje Sucker, Andreas Gast, Stephanie Kadel, Iris Moll, Eduardo Nagore, Kari Hemminki,[...]. Science 2013
18

Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial.
Masatoshi Kudo, Richard S Finn, Shukui Qin, Kwang-Hyub Han, Kenji Ikeda, Fabio Piscaglia, Ari Baron, Joong-Won Park, Guohong Han, Jacek Jassem,[...]. Lancet 2018
17

Whole-genome sequencing of liver cancers identifies etiological influences on mutation patterns and recurrent mutations in chromatin regulators.
Akihiro Fujimoto, Yasushi Totoki, Tetsuo Abe, Keith A Boroevich, Fumie Hosoda, Ha Hai Nguyen, Masayuki Aoki, Naoya Hosono, Michiaki Kubo, Fuyuki Miya,[...]. Nat Genet 2012
574
14

Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial.
Anthony B El-Khoueiry, Bruno Sangro, Thomas Yau, Todd S Crocenzi, Masatoshi Kudo, Chiun Hsu, Tae-You Kim, Su-Pin Choo, Jörg Trojan, Theodore H Welling,[...]. Lancet 2017
14

Systematic analysis of telomere length and somatic alterations in 31 cancer types.
Floris P Barthel, Wei Wei, Ming Tang, Emmanuel Martinez-Ledesma, Xin Hu, Samirkumar B Amin, Kadir C Akdemir, Sahil Seth, Xingzhi Song, Qianghu Wang,[...]. Nat Genet 2017
191
14

Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
Freddie Bray, Jacques Ferlay, Isabelle Soerjomataram, Rebecca L Siegel, Lindsey A Torre, Ahmedin Jemal. CA Cancer J Clin 2018
14

Whole-genome mutational landscape and characterization of noncoding and structural mutations in liver cancer.
Akihiro Fujimoto, Mayuko Furuta, Yasushi Totoki, Tatsuhiko Tsunoda, Mamoru Kato, Yuichi Shiraishi, Hiroko Tanaka, Hiroaki Taniguchi, Yoshiiku Kawakami, Masaki Ueno,[...]. Nat Genet 2016
326
13

Cancer. The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer.
Robert J A Bell, H Tomas Rube, Alex Kreig, Andrew Mancini, Shaun D Fouse, Raman P Nagarajan, Serah Choi, Chibo Hong, Daniel He, Melike Pekmezci,[...]. Science 2015
283
13

Mutations in the promoter of the telomerase gene TERT contribute to tumorigenesis by a two-step mechanism.
Kunitoshi Chiba, Franziska K Lorbeer, A Hunter Shain, David T McSwiggen, Eva Schruf, Areum Oh, Jekwan Ryu, Xavier Darzacq, Boris C Bastian, Dirk Hockemeyer. Science 2017
116
13

Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification.
Julien Calderaro, Gabrielle Couchy, Sandrine Imbeaud, Giuliana Amaddeo, Eric Letouzé, Jean-Frédéric Blanc, Christophe Laurent, Yacine Hajji, Daniel Azoulay, Paulette Bioulac-Sage,[...]. J Hepatol 2017
197
13

Comprehensive analyses of mutations and hepatitis B virus integration in hepatocellular carcinoma with clinicopathological features.
Fukiko Kawai-Kitahata, Yasuhiro Asahina, Shinji Tanaka, Sei Kakinuma, Miyako Murakawa, Sayuri Nitta, Takako Watanabe, Satoshi Otani, Miki Taniguchi, Fumio Goto,[...]. J Gastroenterol 2016
50
26

Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma.
Yujin Hoshida, Sebastian M B Nijman, Masahiro Kobayashi, Jennifer A Chan, Jean-Philippe Brunet, Derek Y Chiang, Augusto Villanueva, Philippa Newell, Kenji Ikeda, Masaji Hashimoto,[...]. Cancer Res 2009
598
12

Specific association of human telomerase activity with immortal cells and cancer.
N W Kim, M A Piatyszek, K R Prowse, C B Harley, M D West, P L Ho, G M Coviello, W E Wright, S L Weinrich, J W Shay. Science 1994
12

Cancer. TERT promoter mutations and telomerase reactivation in urothelial cancer.
Sumit Borah, Linghe Xi, Arthur J Zaug, Natasha M Powell, Garrett M Dancik, Scott B Cohen, James C Costello, Dan Theodorescu, Thomas R Cech. Science 2015
186
12

Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma.
Ghassan K Abou-Alfa, Tim Meyer, Ann-Lii Cheng, Anthony B El-Khoueiry, Lorenza Rimassa, Baek-Yeol Ryoo, Irfan Cicin, Philippe Merle, YenHsun Chen, Joong-Won Park,[...]. N Engl J Med 2018
648
12

Frequency of TERT promoter mutations in human cancers.
João Vinagre, Ana Almeida, Helena Pópulo, Rui Batista, Joana Lyra, Vasco Pinto, Ricardo Coelho, Ricardo Celestino, Hugo Prazeres, Luis Lima,[...]. Nat Commun 2013
496
12

Hepatocellular Carcinoma.
Augusto Villanueva. N Engl J Med 2019
742
12

Genomic profiling of hepatocellular adenomas reveals recurrent FRK-activating mutations and the mechanisms of malignant transformation.
Camilla Pilati, Eric Letouzé, Jean-Charles Nault, Sandrine Imbeaud, Anaïs Boulai, Julien Calderaro, Karine Poussin, Andrea Franconi, Gabrielle Couchy, Guillaume Morcrette,[...]. Cancer Cell 2014
153
11

Trunk mutational events present minimal intra- and inter-tumoral heterogeneity in hepatocellular carcinoma.
Sara Torrecilla, Daniela Sia, Andrew N Harrington, Zhongyang Zhang, Laia Cabellos, Helena Cornella, Agrin Moeini, Genis Camprecios, Wei-Qiang Leow, Maria Isabel Fiel,[...]. J Hepatol 2017
50
22

Molecular Classification of Hepatocellular Adenoma Associates With Risk Factors, Bleeding, and Malignant Transformation.
Jean-Charles Nault, Gabrielle Couchy, Charles Balabaud, Guillaume Morcrette, Stefano Caruso, Jean-Frederic Blanc, Yannick Bacq, Julien Calderaro, Valérie Paradis, Jeanne Ramos,[...]. Gastroenterology 2017
139
11

Identification of an Immune-specific Class of Hepatocellular Carcinoma, Based on Molecular Features.
Daniela Sia, Yang Jiao, Iris Martinez-Quetglas, Olga Kuchuk, Carlos Villacorta-Martin, Manuel Castro de Moura, Juan Putra, Genis Camprecios, Laia Bassaganyas, Nicholas Akers,[...]. Gastroenterology 2017
243
11

Hepatocellular carcinoma.
Josep M Llovet, Jessica Zucman-Rossi, Eli Pikarsky, Bruno Sangro, Myron Schwartz, Morris Sherman, Gregory Gores. Nat Rev Dis Primers 2016
910
10

Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas.
Jean-Charles Nault, Shalini Datta, Sandrine Imbeaud, Andrea Franconi, Maxime Mallet, Gabrielle Couchy, Eric Letouzé, Camilla Pilati, Benjamin Verret, Jean-Frédéric Blanc,[...]. Nat Genet 2015
229
9

Mutational signatures reveal the dynamic interplay of risk factors and cellular processes during liver tumorigenesis.
Eric Letouzé, Jayendra Shinde, Victor Renault, Gabrielle Couchy, Jean-Frédéric Blanc, Emmanuel Tubacher, Quentin Bayard, Delphine Bacq, Vincent Meyer, Jérémy Semhoun,[...]. Nat Commun 2017
90
10

Genomic and oncogenic preference of HBV integration in hepatocellular carcinoma.
Ling-Hao Zhao, Xiao Liu, He-Xin Yan, Wei-Yang Li, Xi Zeng, Yuan Yang, Jie Zhao, Shi-Ping Liu, Xue-Han Zhuang, Chuan Lin,[...]. Nat Commun 2016
111
9

Tumor specific mutations in TERT promoter and CTNNB1 gene in hepatitis B and hepatitis C related hepatocellular carcinoma.
Francesca Pezzuto, Francesco Izzo, Luigi Buonaguro, Clorinda Annunziata, Fabiana Tatangelo, Gerardo Botti, Franco M Buonaguro, Maria Lina Tornesello. Oncotarget 2016
26
34

Hepatitis B virus-related insertional mutagenesis occurs frequently in human liver cancers and recurrently targets human telomerase gene.
Patrizia Paterlini-Bréchot, Kenichi Saigo, Yoshiki Murakami, Mounia Chami, Devrim Gozuacik, Claude Mugnier, David Lagorce, Christian Bréchot. Oncogene 2003
200
9

Genotype-phenotype correlation of CTNNB1 mutations reveals different ß-catenin activity associated with liver tumor progression.
Sandra Rebouissou, Andrea Franconi, Julien Calderaro, Eric Letouzé, Sandrine Imbeaud, Camilla Pilati, Jean-Charles Nault, Gabrielle Couchy, Alexis Laurent, Charles Balabaud,[...]. Hepatology 2016
112
9

Focal gains of VEGFA and molecular classification of hepatocellular carcinoma.
Derek Y Chiang, Augusto Villanueva, Yujin Hoshida, Judit Peix, Philippa Newell, Beatriz Minguez, Amanda C LeBlanc, Diana J Donovan, Swan N Thung, Manel Solé,[...]. Cancer Res 2008
394
9

TERT promoter mutations occur early in urothelial neoplasia and are biomarkers of early disease and disease recurrence in urine.
Isaac Kinde, Enrico Munari, Sheila F Faraj, Ralph H Hruban, Mark Schoenberg, Trinity Bivalacqua, Mohamad Allaf, Simeon Springer, Yuxuan Wang, Luis A Diaz,[...]. Cancer Res 2013
161
9

Cancer-associated TERT promoter mutations abrogate telomerase silencing.
Kunitoshi Chiba, Joshua Z Johnson, Jacob M Vogan, Tina Wagner, John M Boyle, Dirk Hockemeyer. Elife 2015
136
9

Hepatocellular carcinoma.
Alejandro Forner, Josep M Llovet, Jordi Bruix. Lancet 2012
9

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Andrew X Zhu, Yoon-Koo Kang, Chia-Jui Yen, Richard S Finn, Peter R Galle, Josep M Llovet, Eric Assenat, Giovanni Brandi, Marc Pracht, Ho Yeong Lim,[...]. Lancet Oncol 2019
439
9

DNA methylation-based prognosis and epidrivers in hepatocellular carcinoma.
Augusto Villanueva, Anna Portela, Sergi Sayols, Carlo Battiston, Yujin Hoshida, Jesús Méndez-González, Sandrine Imbeaud, Eric Letouzé, Virginia Hernandez-Gea, Helena Cornella,[...]. Hepatology 2015
179
8

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial.
Andrew X Zhu, Richard S Finn, Julien Edeline, Stephane Cattan, Sadahisa Ogasawara, Daniel Palmer, Chris Verslype, Vittorina Zagonel, Laetitia Fartoux, Arndt Vogel,[...]. Lancet Oncol 2018
711
8

The Genetic Evolution of Melanoma from Precursor Lesions.
A Hunter Shain, Iwei Yeh, Ivanka Kovalyshyn, Aravindhan Sriharan, Eric Talevich, Alexander Gagnon, Reinhard Dummer, Jeffrey North, Laura Pincus, Beth Ruben,[...]. N Engl J Med 2015
438
8

Cyclin A2/E1 activation defines a hepatocellular carcinoma subclass with a rearrangement signature of replication stress.
Quentin Bayard, Léa Meunier, Camille Peneau, Victor Renault, Jayendra Shinde, Jean-Charles Nault, Iadh Mami, Gabrielle Couchy, Giuliana Amaddeo, Emmanuel Tubacher,[...]. Nat Commun 2018
33
24

Clinical Impact of Genomic Diversity From Early to Advanced Hepatocellular Carcinoma.
Jean-Charles Nault, Yoann Martin, Stefano Caruso, Théo Z Hirsch, Quentin Bayard, Julien Calderaro, Cecile Charpy, Christiane Copie-Bergman, Marianne Ziol, Paulette Bioulac-Sage,[...]. Hepatology 2020
41
19


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.